Examiner Cite

Remove

Pages,Columns,Lines where

Relevant Passages or Relevant

Passages or Relevant

Figures Appear

Translation of Relevant

Parts Provided

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99

Patent Number

H01-260829

Application Number		10588766
Filing Date		2006-08-08
First Named Inventor KRAL		IS Harald et all.
Art Unit		
Examiner Name		
Attamen Dealest Numb	or	4303 1000

Name of Patentee or Applicant

Document

Initial*	No	T GLOTIC PROTIDOS	Code ¹	laade Date	of cited Doc	ument		Appear	unt
	1								
If you wisi	h to ac	id additional U.S. Par	ent citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite 1	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1								
If you wish	h to ac	id additional U.S. Pul	olished Ap	plication cita	tion information	please click the Ad	d button.	Add	
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner	Cite	Foreign Document	Countr		d Publication	Name of Patente Applicant of cited	e or v	Pages,Columns,Lines	Ts

U.S. PATENTS

Kind

Code2 i

							i
:	2	2000-188278	JP	A	2000-07-04	Translation of Relevant Parts Provided	
3	3	2003-234325	JP	A	2003-08-22	Translation of Relevant Parts Provided	

1989-10-18

Code⁴ Date

Initial* No Number3

	4	2003-332295	JP	^	2003-11-21		Translation of Relevant Parts Provided				
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove				
Examiner Initials*	Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catabg, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										
	Japanese Office Action, dated October 28, 2011, in Application No. 2006-552600.										
	2 Japanese Office Action Translation, dated October 26, 2011, in Application No. 2006-552600.										
If you wish to add additional non-patent literature document citation information please click the Add button Add											
			EX	AMINE	R SIGNATUR	E					
Examiner	Signa	ture				Date Considered					
*FXAMIN	FR: In	itial if reference consid	ered whether or	not cit	ation is in confr	rmance with MPEP 609	Draw line through a				

16e Knd Ooke of USPTO Potent Documents at your USPTO_GOLY or MEPP 801.64. 2 Exter of this that issued the document, by the involved rook (WPO Standard ST3.) 3 for Just purpose patient outcomest, the industrial or of the year of the ringer or respective the serial runber of the patient country.

1 Knd of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.68 if possible. 2 Applicant is to place a check mark here if English languages the relation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10588766			
Filing Date		2006-08-08			
First Named Inventor	KRAL	JS Harald et al.			
Art Unit					
Examiner Name					
Attorney Docket Numb	ec	4303-1009			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

RENOIT CASTEL

_ ...

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

35041

Tomas or and origination			
Signature	/Benoit Castel/	Date (YYYY-MM-DD)	2012-01-04

This collection of Information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Office, u.S. operatment of Comments of Com

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.